GlaxoSmithKline

🇬🇧United Kingdom

Country: 🇬🇧United Kingdom

Ownership: Public

Established: 1929-01-01

Employees: 70.2K

Market Cap: $90B

Website: http://www.gsk.com

Introduction: GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the Commercial Operations, and Research and Development segments. The Commercial Operations segment has three product groups of specialty medicines, vaccines, and general medicines. The company was founded in 1715 and is headquartered in Middlesex, the United Kingdom.

Clinical Trials

Effect of the GSK2245035 on the Allergen-induced Asthmatic Response

Phase 2

Completed

Conditions: Asthma

Interventions: Drug: GSK2245035 Nasal Spray Solution
Drug: Placebo Nasal Spray Solution

First Posted Date: 2016-07-15

Last Posted Date: 2021-03-26

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 36

Registration Number: NCT02833974

Locations: 🇬🇧
GSK Investigational Site, Manchester, United Kingdom

Local Nasal Tolerability and Safety Study of 1146A in Healthy Adult Participants

Phase 1

Completed

Conditions: Common Cold

Interventions: Drug: Carbomer 980
Other: Placebo

First Posted Date: 2016-07-14

Last Posted Date: 2017-06-29

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 30

Registration Number: NCT02832362

Locations: 🇨🇦
GSK Investigational Site, Quebec City, Quebec, Canada

Investigating the Efficacy of an Occluding Dentifrice in Providing Relief From Dentinal Hypersensitivity

Phase 3

Completed

Conditions: Dentin Sensitivity

Interventions: Drug: sodium monofluorophosphate
Drug: stannous fluoride

First Posted Date: 2016-07-14

Last Posted Date: 2017-05-25

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 242

Registration Number: NCT02832375

Locations: 🇺🇸
GSK Investigational Site, Las Vegas, Nevada, United States

A Positron Emission Tomography (PET) Imaging Study to Investigate the Biodistribution and Clearance of an Albumin Binding Domain Antibody (AlbudAb) GSK3128349 in Healthy Male Subjects

Phase 1

Completed

Conditions: Drug-Related Side Effects and Adverse Reactions

Interventions: Drug: 89Zr-GSK3128349 1 mg

First Posted Date: 2016-07-12

Last Posted Date: 2018-09-07

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 8

Registration Number: NCT02829307

Locations: 🇳🇱
GSK Investigational Site, Zuidlaren, Netherlands

Efficacy and Safety Study of GSK1278863 in Japanese Hemodialysis Subjects With Anemia Associated With Chronic Kidney Disease Who Are Not Taking Erythropoiesis Stimulating Agents

Phase 3

Completed

Conditions: Anaemia

Interventions: Drug: GSK1278863
Drug: Iron

First Posted Date: 2016-07-12

Last Posted Date: 2019-12-03

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 28

Registration Number: NCT02829320

Locations: 🇯🇵
GSK Investigational Site, Yamagata, Japan

Warming Sensation and Tolerability Study of Acetylcysteine 2% Oral Solution for Productive Cough

Phase 3

Completed

Conditions: Common Cold

Interventions: Drug: Acetylcystine

First Posted Date: 2016-07-04

Last Posted Date: 2017-01-31

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 58

Registration Number: NCT02822287

Locations: 🇩🇪
GSK Investigational Site, Erfurt, Thueringen, Germany

Efficacy and Safety of GSK1358820 in Subjects With Overactive Bladder

Phase 3

Completed

Conditions: Urinary Bladder, Overactive

Interventions: Drug: GSK1358820
Drug: Placebo
Drug: Antibiotic therapy
Other: King's Health Questionnaire (KHQ)
Other: Bladder diary
Other: Overactive Bladder Symptom Score (OABSS)
Other: Treatment Benefit Scale (TBS)

First Posted Date: 2016-07-01

Last Posted Date: 2020-11-27

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 250

Registration Number: NCT02820844

Locations: 🇯🇵
GSK Investigational Site, Yamanashi, Japan

A Study Comparing the Effect of Albiglutide With Exenatide on Regional Brain Activity Related to Nausea in Healthy Subjects

Phase 4

Terminated

Conditions: Diabetes Mellitus

Interventions: Drug: Albiglutide 50mg
Drug: Albiglutide matching placebo
Drug: Exenatide 10microgram
Drug: Exenatide placebo (saline)

First Posted Date: 2016-06-16

Last Posted Date: 2020-10-30

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 5

Registration Number: NCT02802514

Locations: 🇺🇸
GSK Investigational Site, Boston, Massachusetts, United States

Dose-escalation Study of GSK2330672 in Japanese Healthy Male Volunteers

Phase 1

Completed

Conditions: Cholestasis

Interventions: Drug: GSK2230672
Drug: Placebo

First Posted Date: 2016-06-16

Last Posted Date: 2016-11-09

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 16

Registration Number: NCT02801981

Locations: 🇯🇵
GSK Investigational Site, Tokyo, Japan

Immune Profile in Subjects With New Onset Type 1 Diabetes

Not Applicable

Completed

Conditions: Diabetes Mellitus, Type 1

Interventions: Procedure: Inguinal lymph node fine needle aspirate biopsy
Procedure: Inguinal lymph node core biopsy
Procedure: Peripheral blood collection
Other: Pre- and post-biopsy questionnaire

First Posted Date: 2016-06-16

Last Posted Date: 2019-02-27

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 22

Registration Number: NCT02801942

Locations: 🇬🇧
GSK Investigational Site, Cardiff, United Kingdom

Home Terms & Conditions Privacy Policy